Literature DB >> 17440968

Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate.

Maryla Krajewska1, Allen H Olson, Dan Mercola, John C Reed, Stan Krajewski.   

Abstract

BACKGROUND: Claudins are a family of approximately 23 integral membrane tight junction (TJ) proteins that maintain cell polarity and paracellular barrier functions in epithelial and endothelial cells. Although Claudin-1 was demonstrated to be typically downregulated in various cancers, the precise expression patterns of this protein in normal and neoplastic tissues remain poorly characterized.
METHODS: Using immunohistochemistry, the expression of Claudin-1 was investigated in prostate tissue samples arranged in a tissue microarray (TMA) format and comprising elements of normal prostatic epithelium (n = 6), benign prostatic hyperplasia (BPH; n = 38), prostatic intraepithelial neoplasia (PIN; n = 11), and prostate adenocarcinoma (n = 48). The Claudin-1 expression pattern was compared with that of the basal cell-specific markers, p63, and HMW cytokeratin (34betaE12), by employing double-labeling techniques in conjunction with image analysis methods utilizing color deconvolution algorithms.
RESULTS: In benign prostatic epithelium, pronounced Claudin-1 expression was observed in the basal cell layer with no staining in luminal cells. Prostate adenocarcinoma specimens from 98% (47/48) patients lacked Claudin-1 immunostaining, and no cases contained >5% immunopositive tumor cells.
CONCLUSIONS: Claudin-1 immunohistochemistry should be considered for use as a new diagnostic tool for distinguishing malignant from benign lesions of the prostate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440968     DOI: 10.1002/pros.20578

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  13 in total

1.  Expression of claudins and their prognostic significance in noninvasive urothelial neoplasms of the human urinary bladder.

Authors:  Eszter Székely; Péter Törzsök; Péter Riesz; Anna Korompay; Attila Fintha; Tamás Székely; Gábor Lotz; Péter Nyirády; Imre Romics; József Tímár; Zsuzsa Schaff; András Kiss
Journal:  J Histochem Cytochem       Date:  2011-08-10       Impact factor: 2.479

2.  Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis.

Authors:  A M Szasz; A M Tokes; M Micsinai; T Krenacs; Cs Jakab; L Lukacs; Zs Nemeth; Zs Baranyai; K Dede; L Madaras; J Kulka
Journal:  Clin Exp Metastasis       Date:  2010-10-21       Impact factor: 5.150

3.  Claudin-1 down-regulation in the prostate is associated with aging and increased infiltration of inflammatory cells in BPH.

Authors:  Laura E Pascal; Rajiv Dhir; Goundappa K Balasubramani; Wei Chen; Chandler N Hudson; Pooja Srivastava; Anthony Green; Donald B DeFranco; Naoki Yoshimura; Zhou Wang
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

4.  The Roles of Tight Junctions and Claudin-1 in the Microbubble-Mediated Ultrasound-Induced Enhancement of Drug Concentrations in Rat Prostate.

Authors:  Yonggang Shang; Xiaoxiao Dong; Guangwei Han; Jia Li; Dong Cui; Chengcheng Liu; Longkun Li; Shanhong Yi
Journal:  J Membr Biol       Date:  2015-08-20       Impact factor: 1.843

5.  Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections.

Authors:  Maryla Krajewska; Layton H Smith; Juan Rong; Xianshu Huang; Marc L Hyer; Nikolajs Zeps; Barry Iacopetta; Steven P Linke; Allen H Olson; John C Reed; Stan Krajewski
Journal:  J Histochem Cytochem       Date:  2009-03-16       Impact factor: 2.479

6.  Bcl-B expression in human epithelial and nonepithelial malignancies.

Authors:  Maryla Krajewska; Shinichi Kitada; Jane N Winter; Daina Variakojis; Alan Lichtenstein; Dayong Zhai; Michael Cuddy; Xianshu Huang; Frederic Luciano; Cheryl H Baker; Hoguen Kim; Eunah Shin; Susan Kennedy; Allen H Olson; Andrzej Badzio; Jacek Jassem; Ivo Meinhold-Heerlein; Michael J Duffy; Aaron D Schimmer; Ming Tsao; Ewan Brown; Anne Sawyers; Michael Andreeff; Dan Mercola; Stan Krajewski; John C Reed
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

7.  Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer.

Authors:  Dmitri V Rozanov; Alexei Y Savinov; Roy Williams; Kang Liu; Vladislav S Golubkov; Stan Krajewski; Alex Y Strongin
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

8.  Transforming growth factor beta 1 impairs benign prostatic luminal epithelial cell monolayer barrier function.

Authors:  Feng Li; Laura E Pascal; Ke Wang; Yibin Zhou; Goundappa K Balasubramani; Katherine J O'Malley; Rajiv Dhir; Kai He; Donna Stolz; Donald B DeFranco; Naoki Yoshimura; Joel B Nelson; Tie Chong; Peng Guo; Dalin He; Zhou Wang
Journal:  Am J Clin Exp Urol       Date:  2020-02-25

9.  GLI1 confers profound phenotypic changes upon LNCaP prostate cancer cells that include the acquisition of a hormone independent state.

Authors:  Sandeep K Nadendla; Allon Hazan; Matt Ward; Lisa J Harper; Karwan Moutasim; Lucia S Bianchi; Mahmoud Naase; Lucy Ghali; Gareth J Thomas; David M Prowse; Michael P Philpott; Graham W Neill
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

10.  Overexpression of periostin in stroma positively associated with aggressive prostate cancer.

Authors:  Yuan Tian; Caitlin H Choi; Qing Kay Li; Farah B Rahmatpanah; Xin Chen; Sara Ruth Kim; Robert Veltri; David Chia; Zhen Zhang; Dan Mercola; Hui Zhang
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.